Clinical Trials Logo

HIV Infections clinical trials

View clinical trials related to HIV Infections.

Filter by:

NCT ID: NCT01040091 Completed - HIV Infections Clinical Trials

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status

Start date: December 2009
Phase: Phase 1
Study type: Interventional

Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are two antiretroviral medications used for the treatment and prevention of HIV/AIDS. This study will examine how these medications are processed in the body of people who are HIV-infected, as well as in people who are HIV-uninfected.

NCT ID: NCT01040039 Terminated - HIV Infections Clinical Trials

Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV

Start date: November 2009
Phase: N/A
Study type: Observational

This pilot study aims to study gut B cells in HCV+HIV+, HCV+HIV-, HCV-HIV+, and HCV-HIV- volunteers. Volunteers will undergo a screening blood draw and flexible sigmoidoscopy with biopsy.

NCT ID: NCT01039220 Completed - HIV Infections Clinical Trials

Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients

ANRS 2H
Start date: December 2009
Phase: N/A
Study type: Interventional

To estimate the incidence of H1N1v influenza-like illness and to study the risk factors for serious influenza forms during pandemic period in French HIV infected patients. - Definitions: - Influenza like illness is defined as fever> 37°8C and cough or pharyngalgia. (Centers for Disease Control definition). - Serious forms of influenza-like illness is defined by hospitalization within 14 days onset of symptoms or death attributed to influenza like illness. - Design: - Survey sampling for estimating H1N1v influenza-like illness incidence. - Out of approximately 50 000 patients under follow-up in one of the 40 ANRS centres, a sub-group will be selected by random sampling. Sampling will be stratified by centre and sampling fraction per site will vary in order to select 60 to 80 patients for this study per site. A total of 2500 to 3000 patients will be selected to allow for estimating the incidence of H1N1v influenza-like illness with an adequate precision. Selected patients will be asked to contact the clinical staff on site as soon as any influenza like symptoms appear. In the case of influenza like illness patients are requested to attend to the clinic within 24 hours for physical examination and naso-pharyngeal swab for diagnosis of A(H1N1)v infection. Nested case-control study for the determination of risk factors for serious forms: - Cases: Serious forms (see definition above) identified by any clinical site or hospitalisation unit. - Controls: Patients of the randomly selected sample (see survey sampling above), presenting with influenza-like illness without any criterion for severity. Exhaustivity check: The exhaustivity of symptomatic forms will be assessed a posteriori by merging information from all available data sources.

NCT ID: NCT01038999 Completed - HIV Infection Clinical Trials

Accelerated Aging, HIV Infection, Antiretroviral Therapies

EP 45
Start date: April 2009
Phase: N/A
Study type: Observational

The main goal is to confirm, among HIV1-infected patients, data from in vitro studies showing that antiretroviral therapies induce an accelerated aging through the same mechanisms than genetic laminopathies or than "physiological " aging, that is through the synthesis and persistence of farnesylated prelamin A. The secondary goal is to measure the impact of HIV infection and of antiretroviral therapies on markers of cell ageing (proteasome, mitochondria, telomere). The perspective is to fix antiretroviral therapy side effects using the same drug combination that will be used in few weeks in Marseille to treat children suffering from progeria

NCT ID: NCT01038401 Completed - HIV Infection Clinical Trials

Residual Replication of HIV-1 in the Gut Associated Lymphoid Tissue (GALT) of Patients on Highly Active Antiretroviral Therapy (HAART): the ANRS EP 44 Study

EP 44
Start date: September 2008
Phase: N/A
Study type: Interventional

HIV-1 cannot be eradicated from infected individuals by current antiretroviral regimens. Cellular reservoirs and tissue sanctuary sites allow latent HIV-1 persistence and ongoing low-level virus replication. This project aims to characterize the residual replication of HIV-1 in subjects on antiretroviral therapy, particularly in the gut-associated lymphoid tissue.

NCT ID: NCT01038076 Completed - HIV Infections Clinical Trials

Medications for Chronic HIV: Education and Collaboration

MedCHEC
Start date: December 2009
Phase: N/A
Study type: Interventional

This study will examine whether a computerized, self-administered assessment of patient medication adherence and health behaviors, plus support for adherence, improves the ability of clinicians to identify adherence problems and leads to better adherence.

NCT ID: NCT01034800 Completed - HIV Infections Clinical Trials

The Neuropsychiatric Evaluation of HIV-Positive and Negative Drug Using Individuals: Study 215

Start date: September 2006
Phase: N/A
Study type: Observational

The lack of success in treating substance abuse may be contributed to by a limited understanding of the clinical neurobiology of drug abuse. A better understanding of such deficits might aid in the development of more relevant pharmacological and psychosocial treatment approaches. Thus, the purpose of this study is to test the hypothesis that repetitive illicit drug use may be associated with cortical and subcortical structural abnormalities, vascular abnormalities, as well as neuropsychological decrements. Additionally, a battery of psychological tests are administered to provide information about demographics, drug use, neurocognitive measures, and personality structures....

NCT ID: NCT01033760 Completed - HIV-1 Infections Clinical Trials

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

Start date: April 2010
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to assess the impact of raltegravir, maraviroc, darunavir/r, and Truvada® (emtricitabine/tenofovir) vs. darunavir/r and Truvada® on cell-associated HIV-DNA levels in patients with primary HIV-1 infection.

NCT ID: NCT01032902 Completed - HIV Infections Clinical Trials

Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test

Start date: January 2010
Phase: N/A
Study type: Observational

This study has been designed to evaluate the performance of the Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 rapid test. The device is intended to qualitatively detect the presence of antibodies against HIV-1/2 in oral fluid, whole blood (capillary and venous), serum or plasma. This study will assess the DPP® HIV 1/2 Screen assay's ability to detect HIV-1.

NCT ID: NCT01032408 Completed - Clinical trials for H1N1 Influenza Virus

Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection

Start date: April 2010
Phase: Phase 3
Study type: Interventional

This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of A(H1N1) inactivated influenza virus vaccine in subjects with Human Immunodeficiency Virus Type 1 (HIV-1) Infection and to compare safety and immunogenicity data with a contemporaneously enrolled control group of age-comparable, healthy subjects. Because certain individuals may be hypo-responsive to influenza vaccination, additional studies with high-risk groups are warranted in order to determine the optimal vaccine formulation and dosing schedule for prevention of novel H1N1 virus infection.